Role of Exercise in Chronic Liver Disease Patients Undergoing Liver Transplantation

NCT ID: NCT06163001

Last Updated: 2025-08-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-12-15

Study Completion Date

2025-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this randomised clinical trial (open label) is to test the effect of supervised aerobic and resistance exercises in chronic liver disease patients being planned for living donor liver transplantation (LDLT). The main question it aims to answer are:

* If pre-operative supervised aerobic and resistance exercise for 4 weeks can improve the measures of frailty (Liver frailty index, Short physical performance battery, pulmonary function tests) in chronic liver disease patients being planned for LDLT.
* Can this approach also translate into clinically significant benefits in the postoperative outcomes of LDLT.

Participants will be randomised into two groups receiving either

1. Standard medical therapy along with supervised aerobic and resistance exercises for 4 weeks.
2. Standard medical therapy. The two groups will be compared for progression of the measures of frailty ver the course of their participation as well as their post LDLT outcomes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. Aim and Objective - Primary objective: To assess effects of pre-operative aerobic and resistance exercises in decompensated CLD patients planned for LDLT on the measures of frailty after 1 month of supervised exercise.

Secondary objectives: To assess effects of pre-operative aerobic and resistance exercises in decompensated CLD patients planned for LDLT on the post LDLT outcomes, myostatin levels (on POD 14) and skeletal muscle mass (on POD14).
2. Methodology:

* Study population - Consecutive voluntary adults (\>18 years) with chronic liver disease, planned for living donor liver transplantation fulfilling the conditions as per inclusion and exclusion criteria.
* Study design - Interventional study- Open label randomised controlled trial
* Study period - From time of ethical clearance till 31st December 2024
* Sample size - Assuming median LFI for CLD patients as 3.9 ± 0.3\*, and assuming an improvement of 5% with introduction of exercise along with SMT after 1 follow up, and keeping alpha of 5%, and power of study as 90%, with 1:1 ratio of cases and controls, then by method of change we need to enroll a total of 54 patients with 27 in each arm. Assuming 10% non compliance, a total of 60 cases will be enrolled, with 30 cases in each arm.
* Intervention - Pre-operative supervised exercise-based regimen versus standard medical therapy alone for a minimum duration of 4 weeks.
* Monitoring and assessment - Clinical profile of the patient and symptoms will be serially followed during the patients OPD visits.
* Adverse effects - Exercise may aggravate encephalopathy, metabolic disorders, AKI/HRS. It may also lead to falls due to cardio-pulmonary intolerance or hepatic encephalopathy.
* Stopping rule - Inability to follow the exercise schedule, or development of any of the adverse effects due to exercise as mentioned above.
3. Expected outcome of the project: Better values of measures of frailty and post LDLT outcomes in patients receiving pre-operative concurrent exerises as an intervention.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Liver Disease and Cirrhosis Frailty

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Exercise Group

Group Type EXPERIMENTAL

Supervised aerobic and resistance exercises

Intervention Type BEHAVIORAL

4 weeks of preoperative supervised aerobic and resistance exercises

Dietary supplementation

Intervention Type DIETARY_SUPPLEMENT

4 weeks of preoperative Standard medical therapy which will consist of dietary advice and supplementation

Dietary supplementation

Group Type ACTIVE_COMPARATOR

Dietary supplementation

Intervention Type DIETARY_SUPPLEMENT

4 weeks of preoperative Standard medical therapy which will consist of dietary advice and supplementation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Supervised aerobic and resistance exercises

4 weeks of preoperative supervised aerobic and resistance exercises

Intervention Type BEHAVIORAL

Dietary supplementation

4 weeks of preoperative Standard medical therapy which will consist of dietary advice and supplementation

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

physiotherapy exercise therapy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Voluntary adult patient (\>18 years), decompensated chronic liver disease patients planned for LDLT, and Who pass the screening tests done in the OPD

1. Able to follow the introductory level exercises as per the protocol in the OPD without any adverse event.
2. No drop in the spO2 less than 93% on a 6 minute walk test.

Exclusion Criteria

1. Patients with a physical disability (upper or lower limb deformity/abnormality)
2. Exercise intolerance or inability to follow exercise regime.
3. Patients who fail the screening tests.
4. Patients on the following drugs-

* Higher corticosteroid dose (\>0.1mg/kg/day),
* BCAA (Branched chain amino acids)
* Growth hormone, testosterone, SARMs,
* Ghrelin agonists, myostatin antibodies,
* Activin IIR antagonists, angiotensin converting enzyme inhibitors,
* Espindolol (mixed beta agonist and antagonists), and
* Fast skeletal muscle troponin activators.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Institute of Liver and Biliary Sciences, India

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Viniyendra Pamecha, MS FEBS FRCS(UK)

Role: STUDY_CHAIR

Professor and HOD HPB Surgery and Liver Transplantation

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Institute of Liver and Biliary Sciences

New Delhi, National Capital Territory of Delhi, India

Site Status

Countries

Review the countries where the study has at least one active or historical site.

India

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ILBS-LDLT-02

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.